OBJECTIVE: In rheumatoid arthritis (RA), elevated serum interleukin-34 (IL-34) levels are linked with increased disease severity. IL-34 binds to 2 receptors, macrophage colony-stimulating factor receptor (M-CSFR) and syndecan 1, which are coexpressed in RA macrophages. Expression of both IL-34 and syndecan 1 is strikingly elevated in the RA synovium, yet their mechanisms of action remain undefined. This study was undertaken to investigate the mechanism of action of IL-34 in RA. METHODS: To characterize the significance of IL-34 in immunometabolism, its mechanism of action was elucidated in joint macrophages, fibroblasts, and T effector cells using RA and preclinical models. RESULTS: Intriguingly, syndecan 1 activated IL-34-induced M-CSFR phosphorylation and reprogrammed RA naive cells into distinctive CD14+CD86+GLUT1+ M34 macrophages that expressed elevated levels of IL-1β, CXCL8, and CCL2. In murine M34 macrophages, the inflammatory phenotype was accompanied by potentiated glycolytic activity, exhibited by transcriptional up-regulation of GLUT1, c-Myc, and hypoxia-inducible factor 1α (HIF-1α) and amplified pyruvate and l-lactate secretion. Local expression of IL-34 provoked arthritis by expanding the glycolytic F4/80-positive, inducible nitric oxide synthase (iNOS)-positive macrophage population, which in turn attracted fibroblasts and polarized Th1/Th17 cells. The cross-talk between murine M34 macrophages and Th1/Th17 cells broadened the inflammatory and metabolic phenotypes, resulting in the expansion of IL-34 pathogenicity. Consequently, IL-34-instigated joint inflammation was alleviated in RAG-/- mice compared to wild-type mice. Syndecan 1 deficiency attenuated IL-34-induced arthritis by interfering with joint glycolytic M34 macrophage and osteoclast remodeling. Similarly, inhibition of glycolysis by 2-deoxy-d-glucose reversed the joint swelling and metabolic rewiring triggered by IL-34 via HIF-1α and c-Myc induction. CONCLUSION: IL-34 is a novel endogenous factor that remodels hypermetabolic M34 macrophages and facilitates their cross-regulation with T effector cells to advance inflammatory bone destruction in RA.
OBJECTIVE: In rheumatoid arthritis (RA), elevated serum interleukin-34 (IL-34) levels are linked with increased disease severity. IL-34 binds to 2 receptors, macrophage colony-stimulating factor receptor (M-CSFR) and syndecan 1, which are coexpressed in RA macrophages. Expression of both IL-34 and syndecan 1 is strikingly elevated in the RA synovium, yet their mechanisms of action remain undefined. This study was undertaken to investigate the mechanism of action of IL-34 in RA. METHODS: To characterize the significance of IL-34 in immunometabolism, its mechanism of action was elucidated in joint macrophages, fibroblasts, and T effector cells using RA and preclinical models. RESULTS: Intriguingly, syndecan 1 activated IL-34-induced M-CSFR phosphorylation and reprogrammed RA naive cells into distinctive CD14+CD86+GLUT1+ M34 macrophages that expressed elevated levels of IL-1β, CXCL8, and CCL2. In murine M34 macrophages, the inflammatory phenotype was accompanied by potentiated glycolytic activity, exhibited by transcriptional up-regulation of GLUT1, c-Myc, and hypoxia-inducible factor 1α (HIF-1α) and amplified pyruvate and l-lactate secretion. Local expression of IL-34 provoked arthritis by expanding the glycolytic F4/80-positive, inducible nitric oxide synthase (iNOS)-positive macrophage population, which in turn attracted fibroblasts and polarized Th1/Th17 cells. The cross-talk between murine M34 macrophages and Th1/Th17 cells broadened the inflammatory and metabolic phenotypes, resulting in the expansion of IL-34 pathogenicity. Consequently, IL-34-instigated joint inflammation was alleviated in RAG-/- mice compared to wild-type mice. Syndecan 1 deficiency attenuated IL-34-induced arthritis by interfering with joint glycolytic M34 macrophage and osteoclast remodeling. Similarly, inhibition of glycolysis by 2-deoxy-d-glucose reversed the joint swelling and metabolic rewiring triggered by IL-34 via HIF-1α and c-Myc induction. CONCLUSION: IL-34 is a novel endogenous factor that remodels hypermetabolic M34 macrophages and facilitates their cross-regulation with T effector cells to advance inflammatory bone destruction in RA.
Authors: Sung Hae Chang; Byoong Yong Choi; Jungbum Choi; Jong Jin Yoo; You-Jung Ha; Hyon Joung Cho; Eun Ha Kang; Yeong Wook Song; Yun Jong Lee Journal: Rheumatol Int Date: 2014-06-11 Impact factor: 2.631
Authors: H Asahara; T Hasunuma; T Kobata; H Inoue; U Muller-Ladner; S Gay; T Sumida; K Nishioka Journal: J Rheumatol Date: 1997-03 Impact factor: 4.666
Authors: Jane Falconer; Anne N Murphy; Stephen P Young; Andrew R Clark; Stefano Tiziani; Monica Guma; Christopher D Buckley Journal: Arthritis Rheumatol Date: 2018-06-04 Impact factor: 10.995
Authors: Sarah R Pickens; Nathan D Chamberlain; Michael V Volin; Richard M Pope; Arthur M Mandelin; Shiva Shahrara Journal: Arthritis Rheum Date: 2011-04
Authors: Katrien Van Raemdonck; Sadiq Umar; Karol Palasiewicz; Anja Meyer; Michael V Volin; Huan J Chang; Mina Al-Awqati; Ryan K Zomorrodi; Shiva Shahrara Journal: Immunol Cell Biol Date: 2021-12-06 Impact factor: 5.126
Authors: Sadiq Umar; Karol Palasiewicz; Michael V Volin; Bianca Romay; Rani Rahat; Chandana Tetali; Shiva Arami; Monica Guma; Christian Ascoli; Nadera Sweiss; Ryan K Zomorrodi; Luke A J O'Neill; Shiva Shahrara Journal: Cell Mol Life Sci Date: 2021-10-27 Impact factor: 9.261
Authors: Anja Meyer; Ryan Sienes; Brian Zanotti; Katrien van Raemdonck; Karol Palasiewicz; Daniel P Mass; Michael V Volin; Shiva Shahrara Journal: Cell Mol Immunol Date: 2022-06-08 Impact factor: 22.096
Authors: Sadiq Umar; Karol Palasiewicz; Anja Meyer; Prabhakaran Kumar; Bellur S Prabhakar; Michael V Volin; Rani Rahat; Mina Al-Awqati; Huan J Chang; Ryan K Zomorrodi; Jalees Rehman; Shiva Shahrara Journal: Cell Mol Life Sci Date: 2022-05-19 Impact factor: 9.207